Why Greater Boston?
Massachusetts has long been a destination for scientific excellence, breakthrough innovation and world-class talent.
Today, Alexion is helping shape the next chapter of that story. From our Global Headquarters in Seaport to our rare disease R&D presence in Kendall Square, we bring together scientific expertise, purpose-driven innovation and global reach to help advance therapies for patients who continue to face significant unmet needs.
- Alexion Global Headquarters in Boston Seaport
- Rare Disease R&D presence in Kendall Square
- Part of AstraZeneca's global development engine
- Connected to one of the world's leading life sciences ecosystems
- Collaboration across scientific, medical and commercial functions
Rare Disease Innovation Starts Here
100 Binney Street
A world-leading center for rare disease research, advancing next-generation therapeutics across gene therapy, gene editing, targeted biologics and innovative approaches to diseases where treatment options may be limited or unavailable.
Boston Seaport
Home to Alexion's Global Headquarters, connecting scientific expertise, strategic leadership and commercial excellence to drive impact for patients around the world
Greater Boston-led innovation
Moving science further
Our teams bring together scientific expertise, advanced technologies and leading academic collaborations to help accelerate transformative medicines for patients worldwide.
Built for the future
From AI-enabled discovery to advanced therapeutics, Massachusetts is where diverse teams collaborate to help push the boundaries of what science can do.
Sustainable from the start
Our newest facilities were designed to help science and people thrive, creating environments that support wellbeing, collaboration and sustainability
Why Join Alexion?
Bring your expertise closer to patients
Every breakthrough begins with a deep understanding of the people we serve. Our teams work to advance innovative science while staying connected to the patients, families and communities who inspire our work every day
Turn rare expertise into wider impact
Across Greater Boston, specialists collaborate across scientific disciplines, therapeutic areas and career pathways to help create new possibilities for people living with rare diseases.
Purpose with global scale
As part of AstraZeneca, Alexion combines deep rare disease expertise with the capabilities, resources and reach of a global biopharmaceutical organization. This allows our teams to pursue ambitious science while accelerating impact for patients around the world.
Join Alexion in Greater Boston
Bring your expertise closer to the patients who need it most.
Across Seaport and 100 Binney, Alexion teams are advancing next-generation therapies for people living with rare diseases where treatment options may be limited or unavailable.
Working alongside scientific, medical and commercial leaders, you'll help pioneer new possibilities while connecting your expertise to one of the world's most dynamic life sciences ecosystems.
Explore opportunities across:
- Rare Disease Research
- Translational Science
- Clinical Development
- Gene Therapy
- Gene Editing
- Targeted Biologics
- Medical Affairs
- Global Functions
Join us - Here, it means more.
Apply Now
- Global TAq Lead, Enabling R-261430 Portugal
- Associate Director, Site Supply Chain R-251295 Los Angeles, California
- Statistical Science Director - Late Oncology Hematology R-260944 Wilmington, Delaware
- Director of Alliance Management, Oncology R&D R-261093 Cambridge, Massachusetts
- National Senior Manager, Enterprise Employee Relations R-261507 Mississauga, Canada
- Quantitative Pharmacoepidemiologist R-261503 Mississauga, Canada
- Director, BPM Evidence Publications CVRM R-259217 Gaithersburg, Maryland
- Oncology Market Access Senior Manager R-260595 Gaithersburg, Maryland
- Associate Director, Facilities R-261040 Rockville, Maryland
- Senior Multimodal AI Scientist – Computational Radiology R-261391 Cambridge, Massachusetts
Cell therapy is a unique modality – by engineering living cells to precisely target disease we have the potential to transform patient outcomes across multiple therapeutic areas. At AstraZeneca, we are pioneering cell therapy at scale, investing in state-of-the-art platforms, building global capabilities and pushing the boundaries of science. Our aim is to ensure many more patients can benefit from cell therapy worldwide.
Craig Maxwell-
